Evidence map›Paper›PMID 30575890›Full record

ArticleJAMA neurology2019

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.

Divyanshu Dubey, Sean J Pittock, Karl N Krecke, Padraig P Morris, Elia Sechi, Nicholas L Zalewski, Brian G Weinshenker, Eslam Shosha, Claudia F Lucchinetti, James P Fryer and 12 more

Abstract read
In one paragraph

Article in JAMA neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 2 pooled it
23.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 2 syntheses or guidelines pooled it, 361 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Intractable hiccups as a brainstem red flag: demyelinating disorders with emphasis on neuromyelitis optica spectrum disorder and area postrema syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.Current neurology and neuroscience reports · 2025
    Review
  20. Article

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 2 institutions in 1 country.

Divyanshu DubeyDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Sean J PittockDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Karl N KreckeDepartment of Radiology (Division of Neuroradiology), Mayo Clinic College of Medicine, Rochester, Minnesota.
Padraig P MorrisDepartment of Radiology (Division of Neuroradiology), Mayo Clinic College of Medicine, Rochester, Minnesota.
Elia SechiDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Nicholas L ZalewskiDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Brian G WeinshenkerDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Eslam ShoshaDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Claudia F LucchinettiDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
James P FryerDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
A Sebastian Lopez-ChiribogaDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
John C ChenDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Jiraporn JitprapaikulsanDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Andrew McKeonDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Avi GadothDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
B Mark KeeganDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Jan-Mendelt TillemaDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Elie NaddafDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Marc C PattersonDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Kevin MessacarDepartment of Pediatrics, University of Colorado School of Medicine, Aurora.
Kenneth L TylerDepartment of Neurology, University of Colorado School of Medicine, Aurora.
Eoin P FlanaganDepartment of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota.
Mayo Clinic · USUniversity of Colorado Denver · US

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
NCATS NIH HHS UL1 TR002535
6 · The paper itself

Abstract

Importance: Recognizing the characteristics of myelin oligodendrocyte glycoprotein autoantibody (MOG-IgG) myelitis is essential for early accurate diagnosis and treatment. Objective: To evaluate the clinical, radiologic, and prognostic features of MOG-IgG myelitis and compare with myelitis with aquaporin-4-IgG (AQP4-IgG) and multiple sclerosis (MS). Design, Setting, and Participants: We retrospectively identified 199 MOG-IgG-positive Mayo Clinic patients from January 1, 2000, through December 31, 2017, through our neuroimmunology laboratory. Fifty-four patients met inclusion criteria of (1) clinical myelitis; (2) MOG-IgG positivity; and (3) medical records available. We excluded 145 patients without documented myelitis. Myelitis of AQP4-IgG (n = 46) and MS (n = 26) were used for comparison. Main Outcomes and Measures: Outcome variables included modified Rankin score and need for gait aid. A neuroradiologist analyzed spine magnetic resonance imaging of patients with MOG-IgG and control patients blinded to diagnosis. Results: Of 54 included patients with MOG-IgG myelitis, the median age was 25 years (range, 3-73 years) and 24 were women (44%). Isolated transverse myelitis was the initial manifestation in 29 patients (54%), and 10 (19%) were initially diagnosed as having viral/postviral acute flaccid myelitis. Cerebrospinal fluid-elevated oligoclonal bands occurred in 1 of 38 (3%). At final follow-up (median, 24 months; range, 2-120 months), 32 patients (59%) had developed 1 or more relapses of optic neuritis (n = 31); transverse myelitis (n = 7); or acute disseminated encephalomyelitis (n = 1). Clinical features favoring MOG-IgG myelitis vs AQP4-IgG or MS myelitis included prodromal symptoms and concurrent acute disseminated encephalomyelitis. Magnetic resonance imaging features favoring MOG-IgG over AQP4-IgG or MS myelitis were T2-signal abnormality confined to gray matter (sagittal line and axial H sign) and lack of enhancement. Longitudinally extensive T2 lesions were of similar frequency in MOG-IgG and AQP4-IgG myelitis (37 of 47 [79%] vs 28 of 34 [82%]; P = .52) but not found in MS. Multiple spinal cord lesions and conus involvement were more frequent with MOG-IgG than AQP4-IgG but not different from MS. Wheelchair dependence at myelitis nadir occurred in one-third of patients with MOG-IgG and AQP4-IgG but never with MS, although patients with MOG-IgG myelitis recovered better than those with AQP4-IgG. Conclusions and Relevance: Myelitis is an early manifestation of MOG-IgG-related disease and may have a clinical phenotype of acute flaccid myelitis. We identified a variety of clinical and magnetic resonance imaging features that may help clinicians identify those at risk in whom MOG-IgG should be tested.

Indexed as

AdolescentAdultAgedAutoantibodiesChildChild, PreschoolEncephalomyelitis, Acute DisseminatedFemaleHumansImmunoglobulin GMaleMiddle AgedMyelin-Oligodendrocyte GlycoproteinMyelitis, TransverseNeoplasm Recurrence, LocalNeuromyelitis OpticaAutoantibodiesImmunoglobulin GMyelin-Oligodendrocyte Glycoprotein

Identifiers

PMID30575890
PMCPMC6440233
OpenAlexW2905801855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.